News

Public · Published

NCR Atleos (NYSE:NATL) reports sales below analyst estimates in Q3 2026 earnings

NCR Atleos reported Q3 2026 revenue of $1.1 billion, down 2% from a year earlier and below analysts' $1.14 billion estimate. Its non-GAAP profit was $1.35 per share, above the $1.19 consensus estimate. The company reported pre-tax profit of $129 million and said it had no borrowings on its revolving credit facility.

Published:

Updated:

What happened

NCR Atleos reported Q3 2026 revenue of $1.1 billion, down 2% from a year earlier and below analysts’ $1.14 billion estimate. Its non-GAAP profit was $1.35 per share, above the $1.19 consensus estimate. The company reported pre-tax profit of $129 million and said it had no borrowings on its revolving credit facility.

Confirmed

Global impact / market context

Revenue fell short even as adjusted profit per share beat estimates, showing that stronger earnings did not come from sales growth this quarter. Management said higher cash generation and lower borrowed-money exposure support further debt reduction, but continued revenue weakness could constrain the ability to sustain that improvement.

Analyst inference

The figures present mixed signals for investors: sales declined and missed forecasts, while adjusted profit per share exceeded them. Management also reported higher free cash flow, meaning cash left after business spending, and plans further debt reduction ahead of an anticipated transaction, whose details are not provided.

Analyst inference

What to watch

  1. Watch whether revenue stabilizes after its 2% year-on-year decline; sustained weakness could make it harder to maintain earnings growth without relying on cost control. Analyst inference
  2. Track free cash flow and net leverage, which means borrowed money relative to cash-generating ability, as management says cash generation is enabling further debt reduction. Confirmed
  3. Look for details and timing of the anticipated transaction, which management referenced but did not describe; its terms could affect the company’s financing and debt-reduction plans. Analyst inference

Evidence